Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties?

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 5, 2009, Pages 533-547

  Lombardi, Dario ^a   Cuenoud, Bernard ^b   Krämer, Stefanie D ^a  

^a ETH ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Beta 2 adrenoceptor agonist; Indacaterol; Kinetics; Liposomes; Membrane fluidity; Partitioning; Rafts; Salmeterol; Surface Plasmon Resonance (SPR)

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; INDACATEROL; SALMETEROL;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; LIPID COMPOSITION; LIPID MEMBRANE; LIPID RAFT; MEMBRANE FLUIDITY; MEMBRANE PERMEABILITY; PH; PRIORITY JOURNAL;

ALBUTEROL; DRUG INTERACTIONS; INDANS; LIPOSOMES; MEMBRANE FLUIDITY; MEMBRANE LIPIDS; QUINOLONES;

EID: 70449518003     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.10.001     Document Type: Article

References (56)

1. Abdiche Y.N., and Myszka D.G. Probing the mechanism of drug/lipid membrane interactions using Biacore. Anal. Biochem. 328 (2004) 233-243
2. Anderson G.P., Linden A., and Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur. Respir. J. 7 (1994) 569-578
3. Austin R.P., Barton P., Bonnert R.V., Brown R.C., Cage P.A., Cheshire D.R., Davis A.M., Dougall I.G., Ince F., Pairaudeau G., and Young A. QSAR and the rational design of long-acting dual D2-receptor/beta-2-adrenoceptor agonists. J. Med. Chem. 46 (2003) 3210-3220
4. Avdeef A., Box K.J., Comer J.E., Hibbert C., and Tam K.Y. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm. Res. 15 (1998) 209-215
5. Barnes P.B. Effect of beta-agonists in athsma treatment. In: Powels R., and O'Byrne P.M. (Eds). Beta2-Agonists in Athsma Treatment (1977), Marcel Decker, New York, U.S. 35-64
6. Battram C., Charlton S.J., Cuenoud B., Dowling M.R., Fairhurst R.A., Farr D., Fozard J.R., Leighton-Davies J.R., Lewis C.A., McEvoy L., Turner R.J., and Trifilieff A. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J. Pharmacol. Exp. Ther. 317 (2006) 762-770
7. Beeh K.M., Derom E., Kanniess F., Cameron R., Higgins M., and van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. 29 (2007) 871-878
8. Belli S., Elsener P.M., Wunderli-Allenspach H., and Kramer S.D. Cholesterol-mediated activation of P-glycoprote distinct effects on basal drug-induced ATPase activities. J. Pharm. Sci. 98 (2009) 1905-1918
9. Betageri G.V., and Rogers J.A. Thermodynamic of partitioning of beta-blokers in the n-octanol-buffer and liposome systems. Int. J. Pharm. 46 (1988) 95-102
10. Bouchard G., Pagliara A., Carrupt P.A., Testa B., Gobry V., and Girault H.H. Theoretical and experimental exploration of the lipophilicity of zwitterionic drugs in the 1,2-dichloroethane/water system. Pharm. Res. 19 (2002) 1150-1159
11. Brown D.A., and Rose J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68 (1992) 533-544
12. Bucher K., Besse C.A., Kamau S.W., Wunderli-Allenspach H., and Kramer S.D. Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities. Pharm. Res. 22 (2005) 449-457
13. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
14. Chong L.K., Cooper E., Vardey C.J., and Peachell P.T. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br. J. Pharmacol. 123 (1998) 1009-1015
15. Duringer C., Grundstrom G., Gurcan E., Dainty I.A., Lawson M., Korn S.H., Jerre A., Hakansson H.F., Wieslander E., Fredriksson K., Skold C.M., Lofdahl M., Lofdahl C.G., Nicholls D.J., and Silberstein D.S. Agonist-specific patterns of beta(2)-adrenoceptor responses in human airway cells during prolonged exposure. Br. J. Pharmacol. 158 (2009) 169-179
16. Halayko A.J., Tran T., and Gosens R. Phenotype and functional plasticity of airway smooth muscle: role of caveolae and caveolins. Proc. Am. Thorac. Soc. 5 (2008) 80-88
17. Hellwich U., and Schubert R. Concentration-dependent binding of the chiral beta-blocker oxprenolol to isoelectric or negatively charged unilamellar vesicles. Biochem. Pharmacol. 49 (1995) 511-517
18. Huang C., and Mason J.T. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 308-310
19. Ianoul A., Grant D.D., Rouleau Y., Bani-Yaghoub M., Johnston L.J., and Pezacki J.P. Imaging nanometer domains of beta-adrenergic receptor complexes on the surface of cardiac myocytes. Nat. Chem. Biol. 1 (2005) 196-202
20. Jacobson K., Mouritsen O.G., and Anderson R.G. Lipid rafts: at a crossroad between cell biology and physics. Nat. Cell. Biol. 9 (2007) 7-14
21. Jeppsson A.B., Roos C., Waldeck B., and Widmark E. Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig. Pharmacol. Toxicol. 64 (1989) 58-63
22. Kamau S.W., Kramer S.D., Gunthert M., and Wunderli-Allenspach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In Vitro Cell. Dev. Biol. Anim. 41 (2005) 207-216
23. Kramer S.D. Liposomes/wather partitioning: theory, techniques and applications. In: Testa B., van de Waterbeemd H., Folkers G., and Guy R. (Eds). Pharmacokinetic Optimization in Drug Research (2001), VHCA Wiley-VHC Zurich, Zurich Weinheim 401-428
24. Kramer S.D., Braun A., Jakits-Deiser C., and Wunderli-Allenspach H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propanolol to phosphatidylinositol containing liposomes. Pharm. Res. 15 (1998) 739-744
25. Kramer S.D., Jakits-Deiser C., and Wunderli-Allenspach H. Free fatty acids cause pH-dependent changes in drug-lipid membrane interactions around physiological pH. Pharm. Res. 14 (1997) 827-832
26. Laisc D.D. Liposomes: from Physics to Applications (1993), Elsevier Science Publishers B.V., Amsterdam
27. Lentz B.R. Use of fluorescent probes to monitor molecular order and motions within liposome bilayers. Chem. Phys. Lipids 64 (1993) 99-116
28. Leo A., Hansch C., and Elkins D. Partition coefficients and their uses. Chem. Rev. 71 (1971)
29. Lindberg A., Szalai Z., Pullerits T., and Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 12 (2007) 732-739
30. Lombardi D., Cuenoud B., Wunderli-Allenspach H., and Kramer S.D. Interaction kinetics of salmeterol with egg phosphatidylcholine liposomes by surface plasmon resonance. Anal. Biochem. 385 (2009) 215-223
31. Marsh D. Handbook of Lipid Bilayers (1990), CRC Press, Boston
32. Mayer L.D., Hope M.J., and Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 858 (1986) 161-168
33. Nagle J.F., and Tristram-Nagle S. Structure of lipid bilayers. Biochim. Biophys. Acta 1469 (2000) 159-195
34. Nials A.T., Coleman R.A., Johnson M., and Vardey C.J. The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol. Br. J. Pharmacol. 120 (1997) 961-967
35. Ochsner M., Jaekel K., Mutz M., Anderson M.G., and John P.E. Comparative biophysical analysis of the interaction of bronchodilating beta(2)-adrenoceptor agonists with lipid membranes. Eur. J. Med. Chem. 34 (1999) 451-462
36. Ostrom R.S., Gregorian C., Drenan R.M., Xiang Y., Regan J.W., and Insel P.A. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J. Biol. Chem. 276 (2001) 42063-42069
37. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., and Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 10 (1997) 2484-2489
38. Pauletti G.M., and Wunderli-Allenspach H. Partition coefficients in vitro: artificial membranes as a standardized distribution model. Eur. J. Pharm. Sci. 1 (1994) 273-282
39. Plember van Balen G., Caron G., Ermondi G., Pagliara A., Grandi T., Bouchard G., Fruttero R., Carrupt P.A., and Testa B. Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm. Res. 18 (2001) 694-701
40. Pokorny A., Almeida P.F., Melo E.C., and Vaz W.L. Kinetics of amphiphile association with two-phase lipid bilayer vesicles. Biophys. J. 78 (2000) 267-280
41. Pontier S.M., Percherancier Y., Galandrin S., Breit A., Gales C., and Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J. Biol. Chem. 283 (2008) 24659-24672
42. Razani B., Rubin C.S., and Lisanti M.P. Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J. Biol. Chem. 274 (1999) 26353-26360
43. Rebolj K., Ulrih N.P., Macek P., and Sepcic K. Steroid structural requirements for interaction of ostreolysin, a lipid-raft binding cytolysin, with lipid monolayers and bilayers. Biochim. Biophys. Acta 1758 (2006) 1662-1670
44. Repakova J., Holopainen J.M., Morrow M.R., McDonald M.C., Capkova P., and Vattulainen I. Influence of DPH on the structure and dynamics of a DPPC bilayer. Biophys. J. 88 (2005) 3398-3410
45. Rodgers T., Leahy D., and Rowland M. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J. Pharm. Sci. 94 (2005) 1237-1248
46. Roig J., Hernando R., and Mora R. Indacaterol, a novel once daily inhaled beta2-adrenoreceptor agonist. Open Respir. Med. J. 3 (2009) 27-30
47. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., and Kobilka B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318 (2007) 1266-1273
48. Rybin V.O., Xu X., Lisanti M.P., and Steinberg S.F. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J. Biol. Chem. 275 (2000) 41447-41457
49. Sacre M.M., and Tocanne J.F. Importance of glycerol and fatty acid residues on the ionic properties of phosphatidylglycerols at the air-water interface. Chem. Phys. Lipids 18 (1977) 334-354
50. Seo P.R., Teksin Z.S., Kao J.P., and Polli J.E. Lipid composition effect on permeability across PAMPA. Eur. J. Pharm. Sci. 29 (2006) 259-268
51. Tsamaloukas A., Szadkowska H., and Heerklotz H. Thermodynamic comparison of the interactions of cholesterol with unsaturated phospholipid and sphingomyelins. Biophys. J. 90 (2006) 4479-4487
52. Ullman A., and Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43 (1988) 674-678
53. Voss H.P., Donnell D., and Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur. J. Pharmacol. 227 (1992) 403-409
54. Waldeck B. Beta-adrenoceptor agonists and asthma-100 years of development. Eur. J. Pharmacol. 445 (2002) 1-12
55. Xiang Y., Rybin V.O., Steinberg S.F., and Kobilka B. Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. J. Biol. Chem. 277 (2002) 34280-34286
56. Yu S., Harding P.G., Smith N., and Possmayer F. Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 18 (1983) 522-529